Gyre Therapeutics Ownership | Who Owns Gyre Therapeutics?


OverviewRevenueFinancialsChart

Gyre Therapeutics Ownership Summary


Gyre Therapeutics is owned by 1.70% institutional investors, 87.10% insiders, and 11.20% retail investors. Vanguard group is the largest institutional shareholder, holding 1.29% of GYRE shares.

GYRE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockGyre Therapeutics1.70%87.10%11.20%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group1.15M1.29%$8.58M
Blackrock funding, inc. /de659.40K0.74%$4.92M
Geode capital management374.62K0.42%$2.80M
State street182.75K0.21%$1.36M
Sbi securities167.87K0.19%$1.25M
Charles schwab investment management123.39K0.14%$920.46K
Northern trust116.34K0.13%$867.91K
State of wisconsin investment board39.00K0.04%$290.94K
Bank of new york mellon24.40K0.03%$182.01K
Ubs group22.96K0.03%$171.30K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sbi securities167.87K0.03%$1.25M
Activest wealth management533.000.00%$3.98K
State of wisconsin investment board39.00K0.00%$290.94K
Strs ohio21.10K0.00%$157.41K
Tower research capital llc (trc)2.69K0.00%$20.10K
State of alaska, department of revenue5.22K0.00%$38.00K
Geode capital management374.62K0.00%$2.80M
Ameritas investment partners683.000.00%$5.09K
Northern trust116.34K0.00%$867.91K
Rhumbline advisers13.43K0.00%$100.20K

Top Buyers

HolderShares% AssetsChange
Goldman sachs group18.03K-18.03K
Ubs group22.96K-14.32K
Jane street group12.96K-12.96K
Strs ohio21.10K0.00%7.80K
Royal bank of canada12.39K-6.13K

Top Sellers

HolderShares% AssetsChange
Blackrock funding, inc. /de659.40K0.00%-183.21K
Sbi securities167.87K0.03%-64.43K
Geode capital management374.62K0.00%-27.09K
Northern trust116.34K0.00%-26.99K
Morgan stanley8.98K--26.28K

New Positions

HolderShares% AssetsChangeValue
Jane street group12.96K-12.96K$96.67M
State of alaska, department of revenue5.22K0.00%5.22K$38.00K
Russell investments group1.12K-1.12K$8.38K
Optiver b.v.222.00-222.00$1.66K
Simplex trading164.00-164.00$1.00K

Sold Out

HolderChange
True wealth design-6.00
Us bancorp \de\-17.00
Rise advisors-54.00
Federation des caisses desjardins du quebec-75.00
Cwm-123.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202515-65.12%1,514,519-54.84%112.00%6-80.65%5-28.57%
Jun 30, 2025464.55%3,409,78030.67%341.97%3447.83%7-50.00%
Mar 31, 20254415.79%2,609,38057.10%380.28%2315.00%1455.56%
Dec 31, 20243911.43%1,787,60711.02%259.05%21-4.55%950.00%
Sep 30, 20243516.67%1,610,23828.03%186.89%22-12.00%620.00%

Recent Insider Transactions


DateNameRoleActivityValue
May 28, 2025Ma Songjiang PresidentSell$5.62K
May 27, 2025Ma Songjiang PresidentSell$20.56K
May 23, 2025Ma Songjiang PresidentSell$1.86K
May 22, 2025Ma Songjiang PresidentSell$21.94K
May 20, 2025Ma Songjiang PresidentSell$22.50K

Insider Transactions Trends


DateBuySell
2025 Q3--
2025 Q2-12
2025 Q1-59
2024 Q4-14
2024 Q3--

GYRE Ownership FAQ


Who Owns Gyre Therapeutics?

Gyre Therapeutics shareholders are primarily institutional investors at 1.70%, followed by 87.10% insiders and 11.20% retail investors. The average institutional ownership in Gyre Therapeutics's industry, Biotech Stocks , is 45.22%, which Gyre Therapeutics falls below.

Who owns the most shares of Gyre Therapeutics?

Gyre Therapeutics’s largest shareholders are Vanguard group (1.15M shares, 1.29%), Blackrock funding, inc. /de (659.4K shares, 0.74%), and Geode capital management (374.62K shares, 0.42%). Together, they hold 2.45% of Gyre Therapeutics’s total shares outstanding.

Does Blackrock own Gyre Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Gyre Therapeutics.

Who is Gyre Therapeutics’s biggest shareholder by percentage of total assets invested?

Sbi securities is Gyre Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.03% of its assets in 167.87K Gyre Therapeutics shares, valued at 1.25M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools